Iridex (IRIX) Short term Debt (2020 - 2021)

Iridex's (IRIX) quarterly Short term Debt came in at $2.2 million in Q2 2021, up 74.94% quarter-over-quarter from $1.2 million in Q1 2021.

Iridex (IRIX) Short term Debt (2020 - 2021) Analysis & Trends

Iridex's Short term Debt history runs 2 years deep, the most recent figure standing at $2.2 million for Q2 2021.

On a quarterly basis, Short term Debt changed N/A year-over-year to $2.2 million in Q2 2021; TTM through Apr 2021 was $2.2 million, a N/A change from a year earlier, with the FY2021 full-year figure at $1.2 million, changed N/A from the prior year.
Short term Debt improved to $2.2 million in Q2 2021 per IRIX's latest filing, from $1.2 million in the prior quarter.
Across five years, Short term Debt topped out at $2.2 million in Q2 2021 and bottomed at $1.2 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	Iridex	15.93 Mn	11.33 Mn	4.74 Mn

Download Data